60 Degrees Pharmaceuticals Llc
Clinical trials sponsored by 60 Degrees Pharmaceuticals Llc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial aims to beat exhaustion from Tick-Borne disease Results expected Feb 2027 (estimated)
- Could an antimalarial drug speed recovery from babesiosis? Results expected Mar 2027 (estimated)
-
New drug trial aims to beat exhaustion from Tick-Borne disease
Disease control Recruiting nowThis phase 2 study tests the drug tafenoquine in 40 adults with chronic babesiosis who have severe fatigue. The goal is to see if tafenoquine can reduce fatigue and clear the Babesia parasite from the blood. Participants take the drug and report their fatigue levels using a stand…
Phase 2 • Sponsor: 60 Degrees Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental drug offers hope for stubborn Tick-Borne infection
Disease control Expanded accessThis expanded access program provides tafenoquine, an antimalarial drug, to immunocompromised patients with persistent babesiosis (a tick-borne illness) who haven't gotten better with standard treatments. Participants take the drug daily for 4 days, then weekly until they test ne…
Sponsor: 60 Degrees Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could an antimalarial drug speed recovery from babesiosis?
Disease control Recruiting nowThis study tests whether adding the antimalarial drug tafenoquine to standard care helps hospitalized babesiosis patients recover faster. About 33 adults with confirmed Babesia infection will receive either tafenoquine or a placebo, plus standard antibiotics. Researchers will tra…
Phase 2 • Sponsor: 60 Degrees Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC